Marijke Kamsteeg
Overview
Explore the profile of Marijke Kamsteeg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
822
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dekkers C, Zuithoff N, Bakker D, Knol E, Wevers A, Touwslager W, et al.
Allergy
. 2024 Dec;
PMID: 39673366
Introduction And Objectives: Tralokinumab-a biological that specifically targets interleukin-13-is one of the newer advanced systemic treatments for patients with moderate-to-severe atopic dermatitis (AD). Although safety and efficacy have been shown...
2.
van der Rijst L, Kamphuis E, Schuttelaar M, Hurmuz R, Seyger M, Caron A, et al.
JAMA Dermatol
. 2024 Oct;
161(1):12-21.
PMID: 39412782
Importance: Dupilumab, methotrexate (MTX), and cyclosporine A (CsA) are valuable treatment options for pediatric patients with refractory moderate to severe atopic dermatitis (AD). Yet, comparative data on these treatments in...
3.
Boesjes C, Kamphuis E, de Graaf M, Spekhorst L, Haeck I, van der Gang L, et al.
JAMA Dermatol
. 2024 Aug;
160(10):1044-1055.
PMID: 39110432
Importance: Limited data are available on the long-term effectiveness and safety of dupilumab for atopic dermatitis (AD) in daily practice. Objective: To evaluate clinical effectiveness and reasons for discontinuation of...
4.
Zhang J, Boesjes C, Loman L, Kamphuis E, Romeijn M, Spekhorst L, et al.
J Am Acad Dermatol
. 2024 Apr;
91(2):300-311.
PMID: 38653344
Background: Long-term daily practice data on patient-reported benefits of dupilumab for atopic dermatitis (AD) remains limited. Objective: To evaluate patient-reported outcome measures (PROMs) and the safety of dupilumab in patients...
5.
Kamphuis E, Boesjes C, Loman L, Kamsteeg M, Haeck I, van Lynden-van Nes A, et al.
Acta Derm Venereol
. 2024 Feb;
104:adv19454.
PMID: 38323500
Limited daily practice data on the effect of abrocitinib in patients with atopic dermatitis are available. The aim of this multicentre prospective study is to evaluate the effectiveness and safety...
6.
Kouwenhoven T, van Muijen M, van de Kerkhof P, de Jong E, Kamsteeg M, Seyger M
Pediatr Dermatol
. 2023 Nov;
41(1):34-40.
PMID: 38018272
Background/objectives: Itch is one of the hallmarks of atopic dermatitis (AD), which has a significant impact on the quality of life of pediatric patients with AD and their caregivers. We...
7.
Spekhorst L, Boesjes C, Loman L, Zuithoff N, Bakker D, Kamphuis E, et al.
Br J Dermatol
. 2023 May;
189(3):327-335.
PMID: 37177895
Background: Limited data are available regarding patient-centred dosing of dupilumab for atopic dermatitis (AD) in daily practice. Objectives: To evaluate our patient-centred dupilumab dosing regimen in daily practice, to assess...
8.
Boesjes C, Van der Gang L, Zuithoff N, Bakker D, Spekhorst L, Haeck I, et al.
Acta Derm Venereol
. 2023 Feb;
103:adv00872.
PMID: 36794894
Clinical trials showed that upadacitinib, a selective Janus kinase-1 inhibitor, is effective for treatment of moderate-to-severe atopic dermatitis. However, daily practice studies are limited. This multicentre prospective study evaluated the...
9.
Spekhorst L, de Graaf M, van der Rijst L, Zuithoff N, Schweizer R, Kamsteeg M, et al.
Clin Transl Allergy
. 2023 Jan;
13(1):e12219.
PMID: 36705510
No abstract available.
10.
Kamphuis E, Boesjes C, Loman L, Bakker D, Poelhekken M, Zuithoff N, et al.
Pediatr Allergy Immunol
. 2022 Dec;
33(12):e13887.
PMID: 36564878
Background: Dupilumab has proven to be an effective and safe treatment for atopic dermatitis (AD) in pediatric patients in clinical trials. However, few daily practice studies are available. The aim...